Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells $18,882.58 in Stock

Posted by Brenda Bartman on Jun 25th, 2026

Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Mark Hopman sold 1,258 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $15.01, for a total value of $18,882.58. Following the transaction, the insider directly owned 129,354 shares in the company, valued at approximately $1,941,603.54. The trade was a 0.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

On Thursday, June 4th, Mark Hopman sold 275 shares of Beta Bionics stock. The shares were sold at an average price of $12.31, for a total value of $3,385.25.
On Tuesday, June 2nd, Mark Hopman sold 5,329 shares of Beta Bionics stock. The stock was sold at an average price of $12.61, for a total transaction of $67,198.69.

Beta Bionics Stock Performance

Shares of BBNX traded up $1.18 during mid-day trading on Thursday, hitting $15.91. 1,092,973 shares of the company’s stock were exchanged, compared to its average volume of 1,140,386. The company has a market cap of $708.95 million, a price-to-earnings ratio of -10.54 and a beta of 3.40. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The stock’s 50-day moving average is $11.97 and its 200-day moving average is $15.67.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last posted its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The business had revenue of $27.63 million for the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. As a group, equities research analysts anticipate that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Institutional Investors Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC lifted its stake in Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares during the last quarter. Eversept Partners LP increased its stake in Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after purchasing an additional 736,576 shares during the last quarter. Quantinno Capital Management LP increased its stake in Beta Bionics by 112.9% in the first quarter. Quantinno Capital Management LP now owns 67,879 shares of the company’s stock valued at $680,000 after purchasing an additional 35,996 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Beta Bionics during the 1st quarter worth approximately $720,000. Finally, Granahan Investment Management LLC lifted its position in shares of Beta Bionics by 104.9% during the 1st quarter. Granahan Investment Management LLC now owns 248,449 shares of the company’s stock worth $2,489,000 after buying an additional 127,203 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BBNX. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Bank of America cut their target price on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research note on Monday, May 18th. Stifel Nicolaus reduced their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Weiss Ratings downgraded shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Finally, The Goldman Sachs Group lowered their price target on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Beta Bionics has a consensus rating of “Moderate Buy” and an average target price of $19.70.

Get Our Latest Stock Analysis on BBNX

About Beta Bionics

(Get Free Report)

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.